US FDA Needs More Time To Review Clinuvel’s Scenesse For Phototoxicity
Executive Summary
The user fee goal date for the Food and Drug Administration’s review of Scenesse has been put back from July to October to allow more time to examine the therapy’s benefit-risk profile.
You may also be interested in...
Keeping Track: Scenesse, Reyvow, and Beovu Make Trio Of Novel Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
Clinuvel Completes Arduous Journey To US Approval Of Scenesse
First-in-class drug for rare disease EPP obtains FDA approval, company plans treatment center-based rollout. Scenesse, on the market in Europe since 2016, has faced reimbursement hurdles.
Keeping Track: First RMAT Approval On The Horizon; Big Weeks For Merck, Lilly And Celgene
The latest drug development news and highlights from our US FDA Performance Tracker.